Biomm S.A (BIOM3.SA) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Brazil · ISIN BRBIOMACNOR2

Price
5.35 BRL
Market cap
692.28 m BRL
P/E (2025)
–
P/S (2025)
2.57
Dividend yield
0.00 %
Net margin
-2.48 %
Return on equity (ROE)
-2.13 %
Return on assets (ROA)
-1.28 %

Biomm S.A financials

Fiscal year20242025
Revenue142.91 m BRL269.30 m BRL
Gross profit17.88 m BRL81.77 m BRL
Operating income-81.21 m BRL4.83 m BRL
EBIT-64.99 m BRL4.83 m BRL
Net income-77.24 m BRL-6.69 m BRL
Diluted EPS – continuing operations-0.63 BRL-0.05 BRL

Full history since 2004, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Biomm S.A

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina. The company was incorporated in 2001 and is based in Nova Lima, Brazil.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.